The evolution of multigene panel testing for hereditary cancers

被引:1
|
作者
Frieder, Richard E. [1 ]
Snow, Shari Goldman [2 ]
Francis, Marra S. [3 ]
Brodsky, Burton S. [4 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Womens Hlth Consultants, San Antonio, TX USA
[4] Wayne State Univ, Sch Med, Detroit, MI USA
关键词
D O I
10.1016/j.ajog.2014.08.023
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A thorough family history evaluation remains a critical tool that helps identify those patients who are at risk for hereditary cancer. The American College of Obstetricians and Gynecologists (ACOG) recommends that all women receive a family history evaluation to screen for inherited risk, and that this information be regularly updated. Patients with an abnormal cancer family history need additional follow-up that may include hereditary cancer testing. Multigene panel testing provides comprehensive profiling for hereditary cancer patients by identifying more health risks than single genome testing. If hereditary cancer is established, patients should be counseled about management options, including increased surveillance, chemoprevention, and/or surgery. Establishing workflow protocols may help clinicians integrate hereditary cancer risk assessment into their practice. © 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 123
页数:1
相关论文
共 50 条
  • [1] PERFORMANCE OF MULTIGENE PANEL TESTING IN HEREDITARY PROSTATE CANCER
    Pritzlaff, Mary
    Allen, Kyle
    LaDuca, Holly
    Fantus, Richard
    Helfand, Brian
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E444 - E445
  • [2] Multigene Panel Testing for Hereditary Cancer and Genetic Counseling
    Lee, Eun-Shin
    Kim, Jongjin
    Han, Wonshik
    [J]. TRANSLATIONAL RESEARCH IN BREAST CANCER, 2021, 1187 : 455 - 471
  • [3] Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients
    Ates, Esra Arslan
    Turkyilmaz, Ayberk
    Alavanda, Ceren
    Yildirim, Ozlem
    Guney, Ahmet Ilter
    [J]. MEDENIYET MEDICAL JOURNAL, 2022, 37 (02): : 150 - 158
  • [4] BRACAnalysis and multigene panel testing needs hereditary cancer care
    Kogawa, Takahiro
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 52 - 52
  • [5] Impact of hereditary multigene panel testing for cancer survivors.
    Kapoor, Nimmi S.
    Swisher, Jennifer
    McFarland, Rachel E.
    Patrick, Mychael
    Curcio, Lisa D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03)
  • [6] Multigene panel testing for hereditary breast and ovarian cancers: An analysis of 1303 BRCA-negative Chinese patients
    Kwong, Ava
    Shin, Vivian
    Au, Chun Hang
    Ho, Cecilia
    Chan, Tsun Leung
    Ma, Edmond
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Clinical utility of multigene panel testing for diagnosis of hereditary tumor syndromes
    Iwaizumi, Moriya
    Taniguchi, Terumi
    Fukue, Misaki
    Sugano, Kokichi
    Yoshida, Teruhiko
    Sugimura, Haruhiko
    Maekawa, Masato
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Multigene hereditary cancer panel testing for patients with pancreatic cancer.
    McGill, Anna K.
    Solomon, Sheila R.
    Marshall, Megan L.
    Susswein, Lisa
    Fillman, Corrine
    Skora, Katherine A.
    Postula, Kristen J. Vogel
    Klein, Rachel
    Hruska, Kathleen S.
    Xu, Zhixiong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario
    Jordan Lerner-Ellis
    Chloe Mighton
    Conxi Lazaro
    Nicholas Watkins
    Vanessa Di Gioacchino
    Andrew Wong
    Martin C. Chang
    George S. Charames
    [J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 871 - 879
  • [10] Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario
    Lerner-Ellis, Jordan
    Mighton, Chloe
    Lazaro, Conxi
    Watkins, Nicholas
    Di Gioacchino, Vanessa
    Wong, Andrew
    Chang, Martin C.
    Charames, George S.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (03) : 871 - 879